epocrates logo
epocrates logo
epocrates logo
  • 0

Herbs & Supplements

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Formulary
No Formulary Selected

close

 

Select a medication above to begin.

kanzo

licorice (Glycyrrhiza glabra)

Sections:

  • Entire Monograph
  • Reported Uses
  • Reported Doses
  • Cautions
  • Drug Interactions
  • Adverse Reactions
  • Synonyms
  • Other Info
  • Add to Interaction Check

Reported Uses

  • NOTE: see Herb & Supplement Effectiveness Rating Definitions table
  • acne [Insufficient Evidence]
  • Addison disease [Insufficient Evidence]
  • adrenal insufficiency [Insufficient Evidence]
  • allergic rhinitis [Insufficient Evidence]
  • aphthous ulcer (canker sores) [Possibly Effective]
  • asthma [Insufficient Evidence]
  • atopic dermatitis (eczema) [Possibly Effective]
  • bleeding [Insufficient Evidence]
  • cancer-related pain [Insufficient Evidence]
  • chronic fatigue syndrome [Insufficient Evidence]
  • colic [Insufficient Evidence]
  • COVID-19 [Insufficient Evidence]
  • dental caries prevention [Insufficient Evidence]
  • dental plaque [Insufficient Evidence]
  • depression [Insufficient Evidence]
  • diabetes [Insufficient Evidence]
  • dysmenorrhea [Insufficient Evidence]
  • dyspepsia [Insufficient Evidence]
  • endotracheal intubation-related adverse effects [Possibly Effective]
  • familial Mediterranean fever (FMF) [Insufficient Evidence]
  • hepatitis [Insufficient Evidence]
  • H. pylori infection [Insufficient Evidence]
  • hypercholesterolemia [Insufficient Evidence]
  • hyperkalemia [Insufficient Evidence]
  • hyperprolactinemia, antipsychotic-induced [Insufficient Evidence]
  • IgA vasculitis [Insufficient Evidence]
  • IBS [Insufficient Evidence]
  • lichen planus [Insufficient Evidence]
  • liver CA [Insufficient Evidence]
  • melasma [Insufficient Evidence]
  • menopausal symptoms [Insufficient Evidence]
  • muscle cramps [Insufficient Evidence]
  • metabolic dysfunction-associated steatotic liver disease [Insufficient Evidence]
  • obesity [Insufficient Evidence]
  • oral mucositis, chemo- or XRT-related [Insufficient Evidence]
  • osteoarthritis [Insufficient Evidence]
  • osteoporosis [Insufficient Evidence]
  • Parkinson disease [Insufficient Evidence]
  • peptic ulcer [Insufficient Evidence]
  • physical performance [Insufficient Evidence]
  • polycystic ovary syndrome [Insufficient Evidence]
  • prostate CA [Insufficient Evidence]
  • psoriasis [Insufficient Evidence]
  • SLE [Insufficient Evidence]
  • smoking cessation [Insufficient Evidence]
  • tuberculosis [Insufficient Evidence]
  • urticaria [Insufficient Evidence]
  • vitiligo [Insufficient Evidence]
  • xerostomia [Insufficient Evidence]

Copyright © 2026. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.

Select a medication above to begin.

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information